Cerulean is an oncology-focused product company based in Cambridge, MA. Its platform supports the design of nanopharmaceuticals that effectively target cancerous cells and spare healthy tissue. Nanopharmaceuticals are able to dynamically target tumors by passing through the enlarged pores seen on tumor blood vessels. Once inside, they steadily release a powerful anti-cancer agent (such as camptothecin) over time.
The company was founded based on technologies developed in the Sasisekharan Lab at MIT. Currently, Cerulean has two product candidates in trials – CRLX101, and CRLX301. These therapies are well-tolerated and carry the potential to greatly improve quality of life and patient survival.